This project involves the conduct of diagnostic, natural history assessment and therapeutic clinical trials for inherited immune deficiencies. This project specifically include studies of the diagnostic procedures (including genetic diagnosis), and treatment modalities that are alternatives to allogeneic transplantation and gene therapy (treatment modalities that are the subject of companion projects with the same types of patients). Patients with X-linked severe combined immunodeficiency (XSCID) caused by mutations in the IL2RG gene encoding the common gamma chain (gc) of receptors for interleukins (IL)-2, -4, -7, -9, -15 and -21 often are treated as infants. XSCID patients are studied at NIH who have failed to achieve or maintain immune reconstitution after having as infants received non-conditioning haploidentical parental bone marrow transplants. Such patient often have waning immunity near the end of their first decade of life, and also have associated severe problems with short stature, malnutrition from gastrointestinal malabsorption, various kinds of pulmonary dysfunction, and chronic sinusitis. We have noted a defect in response to growth hormone in such patients and have opened a clinical trial to treat short stature in these pre-adolescent XSCID children. We follow many patients with both autosomal and X-linked forms of chronic granulomatous disease (AR or X-CGD). Patients with CGD have defective circulating blood neutrophils that fail to produce microbicidal hydrogen peroxide. They suffer from recurrent life threatening infections and premature mortality. In addition to recurrent infections including many kinds of difficult to treat fungus infections, CGD patients often have a variety of autoinflammatory syndromes, but we have also noted a high incidence of actual defined autoimmune disorders such as Crohns disease of the gastrointestinal system as well as increased incidence of lupus erythematosis, sarcoidosis, and other syndromes of autoimmunity. We have an ongoing clinical trial of treatment of severe Crohn's-like disease of CGD with TNFa inhibitors such as infliximab. We also are finding that patients with CGD with autoinflammatory lung disease may respond to treatment with methotrexate, though studies are ongoing. Thus, we have increasingly recognized and documented that autoimmune problems can affect patients with a variety of primary immune deficiencies (PID). Many types of PID are more aptly characterized as diseases of immune dysregulation rather than just as immune deficiency with recurrent infections. We published a paper describing two patients in which chronic granulomatous disease appears to have triggered the development of sarcoidosis, an autoimmune disease not generally seen in CGD. This was the first report of sarcoidosis in CGD, but Crohns disease, discoid lupus erythematosis and rheumatoid arthritis have been noted in CGD patients. We proposed in this paper an important new paradigm in understanding CGD, suggesting that there is immune dysregulation associated with CGD that may trigger autoimmune diseases in a subset of patients where the specific autoimmune disease triggered likely related to an individual patients genetic predisposition to a particular autoimmune disease. This has important therapeutic management implications in that specific therapies proven to be effective for the specific autoimmune disease triggered by CGD must be used in such patients rather than just the general clinical management modalities designed to prevent infections, or control the general inflammation common to most CGD patients. In studying granulomatous diseases, we identified an extremely unusual presentation of Rag1 defect as a destructive midline granulomatous disease process that resembles Wegener's granulomatois. This supports our notion of the dysregulation of immunity and hyperinflammation in primary immune deficiencies. We have also in collaboration with Dr. Philip Murphy and Dr. David McDermott in the Lab of Molecular Immunity, NIAID and Dr. Sam Hwang in Dermatology, NCI begun to study the problems that affect patients with WHIM syndrome noting severe neutopenia, increased incidence of human papilloma related cancers and other problems such as chronic pulmonary disease. Studies are in progress to determine better treatments for this disorder. Study of WHIM also interfaced with our related project that seeks to understand the role of CXCR4 (defective in WHIM) in trafficking of hematopoietic cells, including CD34 stem cells into and out of the bone marrow. Our interest in patients with congenital neutropenia led to identification of some patients with syndromic features (venous angiectasia, urogenital and cardiac structural defects) recently attributed to defects in glucose-6-phosphatase, catalytic subunit 3. Studies are in progress to better understand the pathogenesis in this disease. In 2009, our studies in patients with unknown immune deficiencies allowed us to attribute an aggressive granulomatous process causing extensive destruction of critical midline structures in a patient to a compound heterozygote Rag1 mutations, a novel presentation for this defect. Ongoing monitoring studies measuring cytokine production in his peripheral blood mononuclear cells support the hypothesis for dysregulated immunity and hyperinflammation in hypomorphic Rag mutations. A manuscript has been submitted reporting this novel observation and increased understanding of the role of RAG1 in development of regulatory cells that prevent autoimmunity.

Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2009
Total Cost
$559,987
Indirect Cost
City
State
Country
Zip Code
Wingfield, L R; Liu, J; Hu, M et al. (2018) Nine patients with chronic granulomatous disease having selective neck dissection for severe cervical lymphadenitis. Clin Otolaryngol 43:335-340
Marciano, Beatriz E; Zerbe, Christa S; Falcone, E Liana et al. (2017) X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability. J Allergy Clin Immunol :
Brooks, Kristina M; Jarosinski, Paul; Hughes, Thomas et al. (2017) Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach? J Clin Pharmacol :
De Ravin, Suk See; Li, Linhong; Wu, Xiaolin et al. (2017) CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci Transl Med 9:
Sweeney, Colin L; Zou, Jizhong; Choi, Uimook et al. (2017) Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction. Mol Ther 25:321-330
Sowrirajan, Bharatwaj; Saito, Yoshiro; Poudyal, Deepak et al. (2017) Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phox. Sci Rep 7:43441
Merling, Randall K; Kuhns, Douglas B; Sweeney, Colin L et al. (2017) Gene-edited pseudogene resurrection corrects p47phox-deficient chronic granulomatous disease. Blood Adv 1:270-278
Walter, Jolan E; Rosen, Lindsey B; Csomos, Krisztian et al. (2016) Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest 126:4389
Huang, Chengrui; De Ravin, Suk See; Paul, Adam R et al. (2016) Genetic Risk for Inflammatory Bowel Disease Is a Determinant of Crohn's Disease Development in Chronic Granulomatous Disease. Inflamm Bowel Dis 22:2794-2801
Kuhns, Douglas B; Fink, Danielle L; Choi, Uimook et al. (2016) Cytoskeletal abnormalities and neutrophil dysfunction in WDR1 deficiency. Blood 128:2135-2143

Showing the most recent 10 out of 84 publications